ArticleVirology journal2020
Distribution of cervical lesions in high-risk HPV (hr-HPV) positive women with ASC-US: a retrospective single-center study in China.
Article in Virology journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Association between multiple infection patterns of HPV33 and the risk of cervical carcinogenesis.Frontiers in microbiology · 2026Article
- Anti-HPV gel versus interferon α-2b gel as adjuvant therapy after LEEP for HSIL with HR-HPV infection on clinical outcomes, vaginal microecology, and biomarkers of proliferation and immunity.Frontiers in oncology · 2026Article
- Risk-based triage strategy by extended HPV genotyping for women with ASC-US cytology.Annals of medicine · 2025Article
- HPV Infection in Women with ASC-US in Eastern Marmara, Türkiye: Genotype Prevalence and Clinical Implications.International journal of women's health · 2025Article
- Cervical cancer screening: efficacy of PAX1 and JAM3 methylation assay in the triage of atypical squamous cell of undetermined significance (ASC-US).BMC cancer · 2024Article
- Comprehensive overview of genotype distribution and prevalence of human papillomavirus in cervical lesions.Gynecology and obstetrics clinical medicine · 2024Article
- The Diagnostic Significance of Combined Screening and Human Papillomavirus 16 and 18 Cycle Threshold Values for CIN2+ Cervical Lesions.International journal of women's health · 2024Article
- Prevalence of cervical precancers or cancers in women with ASC-H/HSIL cytology according to Aptima HPV (AHPV) assay-detected HPV genotypes and age.Journal of Cancer · 2024Article
- Efficiency of CIN2+ Detection by Thyrotropin-Releasing Hormone (TRH) Site-Specific Methylation.Viruses · 2023Article
- High-risk human papillomavirus genotyping in women with atypical squamous cells of undetermined significance.Scientific reports · 2023Article
- Human papilloma virus infection and its associated risk for cervical lesions: a cross-sectional study in Putuo area of Shanghai, China.BMC women's health · 2023Article
- Analysis of the related factors of atypical squamous cells of undetermined significance (ASC-US) in cervical cytology of post-menopausal women.Frontiers in cellular and infection microbiology · 2023Article
- High-Risk Human Papillomavirus Detection via CobasViruses · 2022Article
- Molecular Detection of Human Papillomaviruses in Formalin Fixed Paraffin Embedded Sections from Different Anogenital Lesions in Duhok-Iraq.Diagnostics (Basel, Switzerland) · 2022Article
- Possible different genotypes for human papillomavirus vaccination in lower middle-income countries towards cervical cancer elimination in 2030: a cross-sectional study.Clinical and experimental vaccine research · 2022Article
- The prevalence and genotype distribution of human papillomavirus among women in Guangxi, southern China.Infectious agents and cancer · 2022Article
- Bioinformatic Analyzes of the Association Between Upregulated Expression ofFrontiers in medicine · 2022Article
- Impact of COVID-19 Outbreak on the Gynecological Outpatients HPV Infection Rate in Wuhan, China: A Retrospective Observational Study.Frontiers in medicine · 2022Article
- Portrayals of 2v, 4v and 9vHPV vaccines on Chinese social media: a content analysis of hot posts on Sina Weibo.Human vaccines & immunotherapeutics · 2021Article
- Significance of the viral load of high-risk HPV in the diagnosis and prediction of cervical lesions: a retrospective study.BMC women's health · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo investigate distributions of cervical lesions and factors associated with the severity of the cervical lesions in high-risk HPV (hr-HPV) positive women with atypical squamous cells of undetermined significance (ASC-US) cytology.
methodsClinical information of 250,000 women who underwent HPV and cytological test was collected from January 2012 to January 2019. The association between the severity of the cervical lesions and hr-HPV genotypes, hr-HPV viral load, and ages, were analyzed in hr-HPV-positive/ASC-US women.
results3459 hr-HPV-positive/ASC-US women were enrolled in this study. Overall, 43.51% of women with ASC-US had normal histological results, 34.35% had high-grade squamous intraepithelial lesion (HSIL), and 1.30% had cervical cancer. The rate of HSIL or worse (HSIL+) in women with single HPV16 infection (63.09%) was the highest, followed by HPV33 (57.50%), HPV51 (36.11%), HPV58 (36.11%), HPV52 (28.28%), HPV18 (26.37%), HPV66 (19.35%), HPV39 (18.92%), HPV53 (15.00%), and HPV56 (8.51%). Detection rate of HSIL+ in low, intermediate and high viral-load groups were 15.87% (n = 30), 34.91% (n = 74) and 40.68% (n = 214) (Cochran-Armitage Trend test χ
conclusionsASC-US women with HPV 16/18/33/51/52/58 single infection and multiple infections, as well as high HPV viral loads, have high risk of HSIL+.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.